Skip to main content

Nirogacestat Side Effects

Applies to nirogacestat: oral tablet.

Warning

Use only as directed. Tell your doctor if you use other medicines or have other medical conditions or allergies.

Get emergency medical help if you have signs of an allergic reaction: hives, difficult breathing, swelling of your face, lips, tongue, or throat.

Call your doctor at once if you have:

Your treatment may be changed, or temporarily or permanently discontinued if you have certain side effects.

Common side effects may include:

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects.

For Healthcare Professionals

Applies to nirogacestat: oral tablet.

General

The most common reactions/laboratory abnormalities occurring in 15% of patients or greater included diarrhea, ovarian toxicity, rash, nausea, fatigue, stomatitis, headache, abdominal pain, cough, alopecia, upper respiratory tract infection, dyspnea, decreased phosphate, increased urine glucose, increased urine protein, increased AST, increased ALT, and decreased potassium.[Ref]

Dermatologic

Very common (10% or more): Rash (68%), alopecia (19%)

Frequency not reported: Hidradenitis suppurativa, folliculitis

Endocrine

Very common (10% or more): Ovarian toxicity (75%)

Ovarian toxicity included ovarian failure, premature menopause, amenorrhea, and menopause.

Gastrointestinal

Very common (10% or more): Diarrhea (84%), nausea (54%), stomatitis (39%), abdominal pain (22%)

Hepatic

Very common (10% or more): Increased aspartate aminotransferase (33%), increased alanine aminotransferase (30%)

Metabolic

Very common (10% or more): Decreased phosphate (65%), decreased potassium (22%)

Oncologic

Frequency not reported: Non-melanoma skin cancers

Other

Very common (10% or more): Fatigue (54%)

Frequency not reported: Influenza-like illness

Renal

Very common (10% or more): Increased urine glucose (51%), increased urine protein (40%)

Respiratory

Very common (10% or more): Cough (20%), upper respiratory tract infection (17%), dyspnea (16%)

Frequency not reported: Epistaxis

Nervous system

Very common (10% or more): Headache (30%)

More about nirogacestat

Patient resources

Other brands

Ogsiveo

Professional resources

Other brands

Ogsiveo

Related treatment guides

References

1. Product Information. Ogsiveo (nirogacestat). SpringWorks Therapeutics, Inc. 2023.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.